Compare Stocks

Abacus Health Products, Inc. manufactures and sells over-the-counter (OTC) topical formulations infused with cannabidiol (CBD) extracted from hemps. The company offers CBD CLINIC line of products for relief from acute musculoskeletal and joint pain, which includes analgesic ointments, creams, and pain sticks, as well as analgesic massage oils. It also provides CBDMEDIC line of products, such as sport ointments and pain sticks, back and neck ointments, arthritis hand creams and ointments, and massage therapy oils, as well as ointments and pain sprays for muscles and joints. The company offers its CBD CLINIC products to registered health practitioners, including chiropractors, acupuncturists, massage and physical therapists, naturopaths, and osteopaths; and CBDMEDIC products directly to consumers through retail pharmacy chains and fitness locations, as well as online through the e-commerce platform. In addition, it is involved in developing a pipeline of other OTC CBD products addressing additional medical indications and the health and wellness sectors. The company is headquartered in Toronto, Canada. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC.

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to treat paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

The SoFi Weekly Income ETF (TGIF) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is the first actively managed USD-denominated fixed income ETF aiming to provide weekly distributions to investors. TGIF was launched on Oct 1, 2020 and is managed by SoFi.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.